安帝君斯

AGEN NASDAQ
2.900
-0.080
-2.68%
已收盘, 16:51 05/22 EDT
开盘
2.970
昨收
2.980
最高
3.020
最低
2.870
成交量
302.29万
成交均量(3M)
105.15万
52周最高
3.880
52周最低
1.540
换手率
2.25%
市值
3.89亿
分时
5日
1月
3月
1年
5年

评论

暂无数据

相关股票

微牛行情栏目提供安帝君斯 AGEN股票价格,安帝君斯股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Agenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company's discovery pipeline includes a range of checkpoint modulating (CPM) antibodies. The Company's vaccine platforms include its heat shock protein (HSP)-based Prophage vaccine candidates, and its synthetic vaccine candidates, ASV and PSV.
展开 >

最近浏览

名称
价格
涨跌幅